Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis

Inclusion Criteria: * 19≤ age ≤ 75 * Have been diagnosed as acute or chronic gastritis with at least 1 erosion by endoscopy within 7 days before enrollment. * Patients understood the consents and purpose of this trial and signed consent form Exclusion Criteria: * Patients who cannot perform endoscopy * Active gastric or duodenal ulcer * Reflux esophagitis, barrett's esophagus, gastric or esophageal varix * Zollinger-Ellison syndrome, pyloric obstruction, and esophageal stricture, Inflammatory Bowel Diease, acute pancreatitis * History of gastrointestinal surgery * History of malignancy tumor, especially in the upper gastrointestinal tract * Severe liver disorder(at screening day, AST or ALT level exceeds 3 times more than normal upper range) * Severe renal disorder(at screening day, MDRD eGFP ≤ 30 mL/min/1.73m2) or chronic renal disease * Bleeding disorder * Patients who have taken drugs containing following list within 2 weeks before endoscopy : H2-receptor antagonists, Proton pump inhibitors, P-CABs, gastrin inhibitors, antacids, gastric mucosal protectants, anticholinergics * Patients who have taken anticoagulants within a week before endoscopy * Patients who have taken drugs containing following list after endoscopy : GI tract regulators, salicylates, steroids, , NSAIDs, bisphosphonates, selective serotonin reuptake inhibitors, iron supplements, oriental herbal medicines * History of allergic reaction to the medications used in this study * Use of other investigational drugs within 30 days prior to the study * History of alcohol or drug abuse * Positive to pregnancy test, nursing mother, intention on pregnancy * Considered by investigator as not appropriate to participate in the clinical study with other reason